(ado-trastuzumab emtansine)

Kadcyla (formerly referred to as T-DM1) consists of our proprietary DM1 cancer-killing agent attached to the HER2-binding antibody, trastuzumab, developed by Genentech (a member of the Roche Group) using our linker and methods of attachment.

Kadcyla Marketing Status

The US FDA granted marketing approval of Kadcyla for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® (trastuzumab) and a taxane chemotherapy. Genentech is the marketer of Kadcyla in the US – please refer to www.kadcyla.com for more information including complete prescribing information.

Kadcyla has been approved in a number of markets outside of the US, including the European Union and Japan. In international markets the timing of commercial availability after approval can vary due to national differences in processes for establishing pricing/reimbursement.

Development of Kadcyla for Additional Indications

Genentech/Roche have a number of clinical trials underway or planned to assess Kadcyla for additional uses. An update on the status of key trials is typically provided in our quarterly financial releases.  

Kadcyla® and Herceptin® are registered trademarks of Genentech, Inc., a member of the Roche Group.

Back to Pipeline

Last updated November 21, 2013